Ledovanc 500 Injection contains Vancomycin 500 mg, a glycopeptide antibiotic used primarily for the treatment of serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and infections caused by penicillin-resistant Streptococcus pneumoniae. It is indicated for the management of severe infections such as bacteremia, endocarditis, osteomyelitis, pneumonia, septicemia, and skin and soft tissue infections where other antibiotics are ineffective or contraindicated. Vancomycin exerts its bactericidal effect by inhibiting bacterial cell wall synthesis, thus preventing cell growth and replication. Ledovanc 500 Injection is administered intravenously, ensuring rapid and effective systemic distribution. Dosage and duration of therapy should be individualized based on the severity of infection, renal function, and patient response, with careful monitoring of serum vancomycin levels to minimize toxicity. Common adverse effects include nephrotoxicity, ototoxicity, infusion-related reactions such as "red man syndrome," and hypersensitivity reactions. Caution is advised in patients with pre-existing renal impairment or hearing loss. Ledovanc 500 Injection should be used under strict medical supervision, with appropriate microbiological testing to confirm susceptibility and guide therapy. It is contraindicated in patients with known hypersensitivity to vancomycin or its components.